• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Savara Inc.

    4/25/25 4:21:14 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SVRA alert in real time by email
    DEFA14A 1 d803807ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    (Rule 14a-101)

    Proxy Statement Pursuant to Section 14(A) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    SAVARA INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


    LOGO

    Your Vote Counts! SAVARA INC. 2025 Annual Meeting SAVARA Vote by June 04, 2025 11 :59 PM ET SAVARA INC. ATIN: CORPORATE SECRETARY ONE SUMMIT SQUARE 1717 LANGHORNE NEWTOWN RD., SUITE 300 LANGHORNE, PA 19047 You invested in SAVARA INC. and it•s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on June 05, 2025. Get informed before you vote View the Form 10 -K, Notice & Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Smartphone users Vote Virtually at the Meeting* Point your camera here and June 05, 2025 3:00PM EDT vote without entering a ~Inumber Virtually at: www.virtualshareholdermeeting.com/SVRA2025 *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1 . To elect six directors to hold office until the next Annual Meeting of Stockholders. Nominees: 1a . Matthew Pauls 0 For 1 b. Nevan Elam 0 For 1c. Richard J. Hawkins 0 For 1d . Joseph S. McCracken 0 For 1e . David A. Ramsay 0 For 1f . An van Es-Johansson 0 For 2. To ratify the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year 0 For ending December 31, 2025. 3. To approve, on an advisory basis, the compensation of our named executives. 0 For 4. To indicate, on an advisory basis, the preferred frequency of holding an advisory vote on the compensation of our 0 Year named executives. NOTE: Such other business as may properly come before the meeting or any adjournment thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

    Get the next $SVRA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SVRA

    DatePrice TargetRatingAnalyst
    5/29/2025$2.00Buy → Neutral
    H.C. Wainwright
    12/20/2024$8.00Overweight
    Wells Fargo
    11/13/2024$7.00 → $5.00Outperform → In-line
    Evercore ISI
    2/15/2024$8.00Mkt Outperform
    JMP Securities
    11/7/2023$7.00Buy
    Guggenheim
    5/16/2023$2.00 → $4.00Hold → Buy
    Jefferies
    3/31/2023$2.00Buy → Hold
    Jefferies
    More analyst ratings

    $SVRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

      Savara Inc. (NASDAQ:SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an RTF letter from the FDA for the BLA of MOLBREEVI as a therapy to treat patients with autoimmune PAP. Upon preliminary review, the FDA determined that the BLA submitted in March 2025 was not sufficiently complete to permit substantive review and requested additional data related to Chemistry, Manufacturing, and Controls (CMC). The RTF was not the result of safety concerns, and the FDA did not request or recommend additional efficacy studies. Within the next 30 days, the Company intends to request a Type A meeting with the Age

      5/27/25 8:05:00 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Savara Announces New Employment Inducement Grant

      Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On May 21, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 85,000 shares of the Company's common stock and restricted stock units (RSUs) covering an aggregate of 75,000 shares of the Company's common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing

      5/23/25 4:05:00 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Savara Announces Participation in Jefferies Global Healthcare Conference

      Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the Jefferies Global Healthcare Conference on June 4, 2025, at 9:20am ET/6:20am PT. The live webcast and subsequent replay will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development

      5/22/25 9:05:00 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SVRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Savara downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Savara from Buy to Neutral and set a new price target of $2.00

      5/29/25 8:15:44 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Savara with a new price target

      Wells Fargo initiated coverage of Savara with a rating of Overweight and set a new price target of $8.00

      12/20/24 7:52:08 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Savara downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Savara from Outperform to In-line and set a new price target of $5.00 from $7.00 previously

      11/13/24 8:25:47 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SVRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hawkins Richard J bought $98,572 worth of shares (48,225 units at $2.04), increasing direct ownership by 72% to 115,466 units (SEC Form 4)

      4 - Savara Inc (0001160308) (Issuer)

      6/23/25 2:39:22 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mccracken Joseph S bought $20,825 worth of shares (10,000 units at $2.08), increasing direct ownership by 4% to 260,837 units (SEC Form 4)

      4 - Savara Inc (0001160308) (Issuer)

      6/2/25 7:59:29 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ramsay David A bought $416,250 worth of shares (150,000 units at $2.77), increasing direct ownership by 6% to 2,513,642 units (SEC Form 4)

      4 - Savara Inc (0001160308) (Issuer)

      4/1/25 7:00:04 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hawkins Richard J bought $98,572 worth of shares (48,225 units at $2.04), increasing direct ownership by 72% to 115,466 units (SEC Form 4)

      4 - Savara Inc (0001160308) (Issuer)

      6/23/25 2:39:22 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mccracken Joseph S bought $20,825 worth of shares (10,000 units at $2.08), increasing direct ownership by 4% to 260,837 units (SEC Form 4)

      4 - Savara Inc (0001160308) (Issuer)

      6/2/25 7:59:29 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ramsay David A bought $416,250 worth of shares (150,000 units at $2.77), increasing direct ownership by 6% to 2,513,642 units (SEC Form 4)

      4 - Savara Inc (0001160308) (Issuer)

      4/1/25 7:00:04 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SVRA
    SEC Filings

    See more
    • SEC Form 8-K filed by Savara Inc.

      8-K - Savara Inc (0001160308) (Filer)

      6/6/25 4:48:34 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Savara Inc.

      8-K - Savara Inc (0001160308) (Filer)

      5/27/25 8:13:24 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Savara Inc.

      10-Q - Savara Inc (0001160308) (Filer)

      5/13/25 4:03:22 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SVRA
    Financials

    Live finance-specific insights

    See more
    • Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

      Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint) Statistically Significant Improvement in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 24 (Secondary Endpoint) 97% of Patients Completed Double-Blind Treatment Through Week 48 with No Trial Drug Related Adverse Events Leading to Discontinuation 100% of Patients Completing the 48-Week Double-Blind Period Elected to Participate in the 96-Week Open-Label Period Company Plans to Complete BLA Submission in 1H 2025 Company to Host Webcast Conference Call Today, Ju

      6/26/24 6:30:00 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

      Conference Call to Take Place Tomorrow, Wednesday, June 26, 2024, at 8:00am ET Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top line results from the pivotal, Phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of molgramostim, an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with aPAP. The Company plans to issue a press release sharing the top line results at approximately 6:30am ET tomorrow, prior to the start of the c

      6/25/24 8:05:00 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SVRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

      Mr. Parker has More Than 25 Years of Commercial Leadership Experience and has Launched Multiple Rare Disease Products Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointment of Braden Parker as Chief Commercial Officer, effective immediately. Mr. Parker is a seasoned global commercial leader with more than 25 years of experience in the healthcare and biotech industry. Throughout his career, he has developed and executed global commercial plans, including market expansion activities, built high-performance teams, and launched multiple successful rare disease products. Mr. Parker is responsible

      9/24/24 8:05:00 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

       Pivotal Phase 3 IMPALA-2 Trial Remains On-Track, Top Line Data Expected End of 2Q 2024 IMPALA-2 is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease Received Acceptance from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) on a Revised Pediatric Investigation Plan (PIP) for Molgramostim in aPAP Appoints Raymond Pratt, M.D., Chief Medical Officer Company Ends Quarter with ~$134M, Believes it is Sufficiently Capitalized Through 2025 Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory disease

      11/10/22 4:05:00 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Savara Announces Resignation of Chief Medical Officer

      Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical Officer, effective September 9, 2022. "We appreciate Dr. Chowdhury's contributions during his tenure with the company," said Matt Pauls, Chair and CEO, Savara. "His leadership helped progress our molgramostim nebulizer solution (molgramostim) development program through some important milestones and we wish him well in the future." "I am pleased to have been part of the Savara team and wish the company success in the continued development of molgramostim for the treatment of the rare lung

      8/26/22 8:05:00 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SVRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Savara Inc.

      SC 13G - Savara Inc (0001160308) (Subject)

      11/27/24 11:01:58 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Savara Inc.

      SC 13G/A - Savara Inc (0001160308) (Subject)

      11/14/24 5:48:34 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Savara Inc.

      SC 13G/A - Savara Inc (0001160308) (Subject)

      11/12/24 10:25:33 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care